Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report ; volume:14 ; number:2 ; year:2021 ; pages:1134-1138 ; extent:5
Case reports in oncology ; 14, Heft 2 (2021), 1134-1138 (gesamt 5)
- Urheber
-
Moghimi, Minoosh
Khodadadi, Kasra
- DOI
-
10.1159/000517819
- URN
-
urn:nbn:de:101:1-2021090900441535475415
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Moghimi, Minoosh
- Khodadadi, Kasra
Ähnliche Objekte (12)
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations